Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $10.33 Average PT from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given a consensus recommendation of “Moderate Buy” by the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.33.

Several equities research analysts have issued reports on MRVI shares. Wells Fargo & Company started coverage on shares of Maravai LifeSciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 price target on the stock. Wolfe Research started coverage on shares of Maravai LifeSciences in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Royal Bank of Canada decreased their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Robert W. Baird decreased their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Finally, The Goldman Sachs Group decreased their target price on shares of Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 8th.

Maravai LifeSciences Trading Up 5.2 %

MRVI opened at $5.22 on Friday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -3.18 and a beta of 0.02. Maravai LifeSciences has a 12 month low of $4.28 and a 12 month high of $11.56. The firm’s fifty day simple moving average is $7.37 and its 200 day simple moving average is $8.27. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.

Insider Activity at Maravai LifeSciences

In other Maravai LifeSciences news, insider Carl Hull purchased 175,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $5.64 per share, with a total value of $987,000.00. Following the completion of the purchase, the insider now owns 175,000 shares of the company’s stock, valued at approximately $987,000. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.63% of the stock is owned by insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Large investors have recently modified their holdings of the business. Creative Planning raised its stake in Maravai LifeSciences by 4.4% during the third quarter. Creative Planning now owns 44,943 shares of the company’s stock worth $373,000 after buying an additional 1,881 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Maravai LifeSciences by 310.2% during the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after purchasing an additional 2,711 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Maravai LifeSciences by 5.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 73,595 shares of the company’s stock worth $639,000 after purchasing an additional 3,575 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its holdings in Maravai LifeSciences by 0.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock worth $4,320,000 after purchasing an additional 3,725 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Maravai LifeSciences in the second quarter worth about $32,000. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.